Clinical Trial Update: Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser [NA]

View source ↗

Summary

A completed trial evaluating how the FXCorDiax 100 dialyzer clears middle-sized molecules relative to the FX 100 and Polyflux 210 H dialyzers in patients on chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• FX 100 (dialyzer)
• FXCorDiax 100 (dialyzer)
• Polyflux 210 H Dialyser (dialyzer)

Snippet

Sponsor: Kantonsspital Aarau | Conditions: Renal Failure Chronic Requiring Hemodialysis | NA | Status: COMPLETED